21:10 , Jun 21, 2018 |  BC Innovations  |  Translation in Brief

Liver’s killer instinct

A study in Science suggests natural killer T cells residing in the liver uniquely position the organ to reap antitumor effects from antibiotic-mediated microbiome depletion, uncovering a novel link in the microbiome-cancer relationship that highlights...
21:06 , May 16, 2018 |  BC Extra  |  Preclinical News

Nanoparticle pretreatment could boost solid tumor CAR T therapy

Research from the University of Washington and the Fred Hutchinson Cancer Research Center suggests preconditioning cancer patients with immunomodulatory nanoparticles could increase the efficacy of CAR T therapies to treat solid tumors. The main hypothesis...
00:47 , Jul 13, 2016 |  BC Extra  |  Company News

Cell Medica acquiring Delenex

Cell Medica Ltd. (London, U.K.) is acquiring Delenex Therapeutics AG (Zurich, Switzerland) for undisclosed terms. Cell Medica plans to use Delenex's PENTRA antibody fragment platform to develop next-generation chimeric antigen receptor (CAR)-modified cellular immunotherapies. Delenex's...
08:00 , Feb 8, 2016 |  BioCentury  |  Product Development

Asthma armament

Amgen Inc .'s AMG 282 could allow Genentech Inc. to treat an asthma patient population not currently covered by its existing pipeline - or by any other targeted therapies in the clinic. The mAb has...
07:00 , Sep 17, 2015 |  BC Innovations  |  Finance

NIAAA focuses on developing medicines

NIH's National Institute on Alcohol Abuse and Alcoholism took steps this summer to underscore its support for translational research with new plans for a division dedicated to developing drugs for alcohol use disorder. According to...
07:00 , Mar 12, 2015 |  BC Innovations  |  Product R&D

Extending zinc fingers

After test-driving its gene editing technology in hemophilia through a partnership with Shire plc , Sangamo BioSciences Inc. is expanding its zinc finger nuclease platform to two new indications, Hurler syndrome and Hunter syndrome. This...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Clinical News

PV-10: Phase I data

Researchers at the Moffitt Cancer Center reported data from 8 melanoma patients in an open-label, U.S. Phase I trial showing that intralesional PV-10 led to significant reductions in melanoma cells in injected tumors and in...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Clinical News

RGI-2001: Phase I/II ongoing

Regimmune began the Phase II portion of an open-label, U.S. Phase I/II trial of IV RGI-2001 in leukemia patients given 30 minutes following allogeneic HSCT. The Phase I portion evaluated escalating doses of RGI-2001 to...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Clinical News

Anti-NKG2D: Phase II planned

Novo Nordisk disclosed in its 2013 earnings that it plans to resume Phase II testing of NN8555 to treat CD. The company could not be reached for details. In 2012, Novo Nordisk discontinued development of...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

IPH 2101: Interim Phase I data

Interim data from the open-label, U.S. Phase I KIRIMID trial in 14 patients with relapsed MM after 1-2 prior lines of therapy showed that IV IPH2101 on day 1 plus Revlimid lenalidomide on days 1-21...